This HTML5 document contains 140 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n12http://dx.doi.org/10.1136/
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n11http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q37210207
rdf:type
wikibase:Item
schema:description
научни чланак vetenskaplig artikel artículu científicu espublizáu en 2008 bilimsel makale scientific article published on 15 September 2008 artigo científico videnskabelig artikel article scientifique wetenschappelijk artikel مقالة علمية نشرت في 15 سبتمبر 2008 article científic wissenschaftlicher Artikel articolo scientifico наукова стаття, опублікована у вересні 2008 vedecký článok vědecký článek
p:P577
wds:Q37210207-5AF4FC10-5C89-44A1-AAB1-F6978E672BB7
wdt:P577
2008-09-15T00:00:00Z
p:P407
wds:Q37210207-F7948A97-4808-4ED1-A18E-1BC3E82E8551
wdt:P407
wd:Q1860
p:P2860
wds:Q37210207-63F12654-AE2A-44F5-9B3C-DAD22E7CD4DD wds:Q37210207-4A56F89A-D1A8-4037-BB8F-A99D8006F41E wds:Q37210207-4D3008B2-6EED-47AA-B3A9-5A7EFBD6A1F5 wds:Q37210207-513233CD-0CEC-42BC-85C8-60C5107A9F7C wds:Q37210207-D6D3C1CF-6FE1-479D-A0B3-0AEFA7A3DC4F wds:Q37210207-DFF3D0AD-7AB6-4BE4-B786-B524CE09127E wds:Q37210207-BDBB3749-AAE9-4AED-98DE-F4B07563B135 wds:Q37210207-C9E48BCD-4449-412B-B605-07BAE8DBD419 wds:Q37210207-FB2A7A72-90AB-48B5-BB65-61406CBB0ED6 wds:Q37210207-E960036C-5D07-4783-ACEA-1A0550A7163F wds:Q37210207-29691BDF-9E40-4ADD-9AC8-4E0E867F1A9C wds:Q37210207-0CC91264-9300-4CFB-8235-DAA72A0A4D28 wds:Q37210207-206F7C3C-4243-418A-BB36-3A36A6607D5B wds:Q37210207-8AAF490C-125D-4B06-A5C0-85C6AE9EE027 wds:Q37210207-96105E6C-19B1-4204-816F-8E8974925159 wds:Q37210207-98C33B7B-B559-4293-A4ED-00E316606A87 wds:Q37210207-9F094047-5CDD-4401-B537-A80182C62A42 wds:Q37210207-7A5EAB00-B2EC-4549-B057-D0008BA7B8DC wds:Q37210207-88011040-E5D7-4178-B4CF-A28BE73BD909 wds:Q37210207-B43EEDB0-C368-40B7-B5C5-23A0CD1555AE wds:Q37210207-B888B6EB-0EA2-4B58-B2A2-878D6AECB802 wds:Q37210207-B940583F-B7A2-47BC-AAE4-2AE0D7EA9A7E wds:Q37210207-A135F470-1F7B-41C1-88EA-3440C2993061 wds:Q37210207-AD5101B2-1E24-4D4F-9ABC-2331C689F762 wds:Q37210207-47CEC04D-E45D-4D6D-8F90-7A5E299425B5 wds:Q37210207-2D07EE3B-1B77-48FF-98C2-7CB99033905A wds:Q37210207-322007FA-13B6-43AF-A28F-E7D9C67EA0C1
wdt:P2860
wd:Q35555309 wd:Q35036985 wd:Q35549178 wd:Q35953458 wd:Q35953319 wd:Q44366478 wd:Q28295474 wd:Q36013828 wd:Q49031401 wd:Q42603607 wd:Q36356750 wd:Q47643186 wd:Q35638252 wd:Q73252625 wd:Q44916043 wd:Q72872862 wd:Q73065125 wd:Q24556513 wd:Q77341367 wd:Q34547981 wd:Q34544500 wd:Q80209325 wd:Q70672405 wd:Q44398367 wd:Q35637985 wd:Q33885648 wd:Q35638208
p:P2093
wds:Q37210207-CD23C5BD-E4B9-4B00-957F-9766EF27B2A7 wds:Q37210207-D2B63B90-4B32-4413-9997-4F5168FDB6D9 wds:Q37210207-F23ADEFB-3D77-439A-8019-6C95287D142C wds:Q37210207-34BCDB39-1D40-40AC-83A4-1DA004AC208D wds:Q37210207-3E644D10-E0B0-4CF3-B043-BEB07C4EB10B wds:Q37210207-47C05362-3FF2-4EFE-A9A1-DC32A53EED75 wds:Q37210207-45C49EB1-4CCE-4E6F-BF7E-364E27966596 wds:Q37210207-6E7EE3D6-4578-44A6-9FF2-DEE92002A26F wds:Q37210207-7943663A-53E8-42FE-AE50-37910CB86F5B wds:Q37210207-88DF71FB-1F82-4F5B-8FC0-1E458627C120 wds:Q37210207-8435D80C-B1BF-430D-9C20-3EB66DB73EB4 wds:Q37210207-BDA57C3F-ECD0-4D46-AF65-1099397B444C wds:Q37210207-2B6BD6F9-F4FC-4794-B0C6-1452955E0A90
wdt:P2093
J S Smolen J Wajdula K Pavelka R Khandker P N Sambrook Etanercept European Investigators Network S Fatenejad C Codreanu M Gaubitz A Singh U Fiocco B Combe P P Geusens
rdfs:label
Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomised 2-year study Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomised 2-year study Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomised 2-year study
skos:prefLabel
Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomised 2-year study Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomised 2-year study Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomised 2-year study
schema:name
Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomised 2-year study Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomised 2-year study Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomised 2-year study
p:P50
wds:Q37210207-480DE5DC-C0C1-410B-98ED-A9E82D0A7AA0
wdt:P50
wd:Q65660760
p:P1476
wds:Q37210207-D5957C18-4853-4AEB-A694-01A466680786
wdt:P1476
Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomised 2-year study
p:P304
wds:Q37210207-F5FCE3F9-105E-4971-BA4D-F535CB18840C
wdt:P304
1146-1152
p:P31
wds:Q37210207-06F34951-F5A5-4066-A790-E7286285A818
wdt:P31
wd:Q13442814
p:P921
wds:Q37210207-A27EDF28-7CEE-4AA6-94D8-C9E01E7F44AF wds:Q37210207-1A8AB352-B2EF-41D0-B865-B830548470EA wds:Q37210207-F01214C7-C020-4AD3-9FFA-E6FFD5D23E2B
wdt:P921
wd:Q187255 wd:Q181600 wd:Q420035
p:P698
wds:Q37210207-20C0D494-3FCD-4D63-9250-FB0031CD4D22
wdtn:P698
n11:18794178
wdt:P698
18794178
p:P1433
wds:Q37210207-B43B60C7-1690-4401-83F1-641B2D0C38B3
wdt:P1433
wd:Q4767876
p:P433
wds:Q37210207-F98A6A3F-274F-40FA-9E23-1F24540246E1
p:P478
wds:Q37210207-E2F299C9-BA60-4A7E-B239-923AB4EEB5ED
wdt:P433
7
wdt:P478
68
p:P356
wds:Q37210207-4107E21F-7FE2-4DDA-A8FC-4335A0A066DB
wdtn:P356
n12:ARD.2007.087106
wdt:P356
10.1136/ARD.2007.087106
p:P5875
wds:Q37210207-23B71EE7-AFE5-4D97-8837-FE89916D3F16
wdt:P5875
23258054
p:P932
wds:Q37210207-1D96B923-8FCA-4179-92DD-CE904494100F
wdt:P932
2689524